|
|
|
| Application effect of Oxycodone combined with Dexmedetomidine in CTguided radiofrequency ablation of pulmonary nodules |
| WEI Guo-hua WANG Juan▲ |
| Department of Anesthesiology, the First Affiliated Hospital of Nanjing Medical University |
|
|
|
|
Abstract Objective To investigate the application effect of Oxycodone combined with Dexmedetomidine in CT-guided radiofrequency ablation of pulmonary nodules.Methods A total of 60 patients who underwent CT-guided radiofrequency ablation of pulmonary nodules in our hospital from March 2018 to September 2019 were selected as the research subjects, aged≤65 years old, American Society of Anesthesiologists (ASA) grade Ⅰand Ⅱ, size of the nodules was ≤3 cm, and they were divided into the control group (30 cases) and the experimental group (30 cases) according to the random number table method.Patients in the control group were anesthetized with Propofol combined with Remifentanil, Propofol at a dose of 1 mg/kg was slowly injected, and the Remifentanil was continuously infused at a dose of 2 mg/(kg·h) until the end of the operation.Patients in the experimental group were anesthetized with Oxycodone combined with Dexmedetomidine, intravenously injected with Oxycodone 0.2 mg/kg, and intravenous injection of Dexmedetomidine 1 μg/kg (pumped within 10 minutes), followed by the speed of 0.2 μg/(kg·h) maintained until the end of the operation.The heart rate (HR), pulse oxygen saturation (SpO2) and mean arterial pressure (MAP) when entering the room (T0), when the operation started (T1), when the operation started 10 minutes (T2), when the operation ended(T3), after the operation ended 10 minutes (T4) of the two groups of patients were recorded.The recovery time of the two groups of patients was compared and the visual analogue scale (VAS) scores of the two groups of patients at the time of waking up (t0), 10 min after waking up (t1) and 30 min after waking up (t2) were recorded.The incidence of adverse reactions, such as respiratory depression, intraoperative hypotension, body movement and nausea and vomiting, was recorded in both groups.Results The recovery time of the experimental group was shorter than that of the control group, and the difference was statistically significant (P＜0.05).There were no statistically significant differences in HR,MAP and SpO2 at T0, T1, T2, T3 and T4 between the two groups of patients (P＞0.05).The VAS score at t2 and the incidence rate of respiratory depression in the experimental group were lower than those in the control group, the differences were statistically significant (P＜0.05).Conclusion Oxycodone combined with Dexmedetomidine can be safely and effectively used in CT-guided radiofrequency ablation of pulmonary nodules
|
|
|
|
|
|
| [3] |
Mu L，Pan T，Lyu N，et al.CT-guided percutaneous radiofrequency ablation for lung neoplasms adjacent to the pericardium[J].Lung Cancer，2018，122：25-31.
|
| [1] |
Chen T，Jin J，Chen S.Clinical assessment of computed tomography guided radiofrequency ablation in the treatment of inoperable patients with pulmonary tumors[J].J Thorac Dis，2017，9（12）：5131-5142.
|
| [2] |
Lencioni R，Crocetti L，Cioni R，et al.Response to radiofrequency ablation of pulmonary tumours：a prospective，intentionto-treat，multicentre clinical trial （the RAPTURE study）[J].Lancet Oncol，2008，9（7）：621-628.
|
| [4] |
De Baere T，Tselikas L，Gravel G，et al.Lung ablation：Best practice/results/response assessment/role alongside other ablative therapies[J].Clin Radiol，2017，72（8）：657-664.
|
| [5] |
Chen H，Senan S，Nossent EJ，et al.Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease：A Systematic Review[J].Int J Radiat Oncol Biol Phys，2017，98（3）：622-631.
|
| [6] |
Lee S，Rhim H，Kim YS，et al.Percutaneous Radiofrequency Ablation of Hepatocellular Carcinomas：Factors Related to Intraprocedural and Postprocedural Pain[J].AJR Am J Roentgenol，2009，192（4）：1064-1070.
|
| [7] |
Wysowski DK，Pollock ML.Reports of Death with Use of Propofol （Diprivan） for Nonprocedural （Long-term） Sedation and Literature Review[J].Anesthesiology，2006，105（5）：1047-1051.
|
| [8] |
Weerink M，Struys M，Hannivoort LN，et al.Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine[J].Clin Pharmacokinet，2017，56（8）：893-913.
|
| [9] |
Lin Y，Zhang R，Shen W，et al.Dexmedetomidine Versus Other Sedatives for Non-Painful Pediatric Examinations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials[J].J Clin Anesth，2020，62：109 736.
|
| [10] |
Arain SR，Ruehlow RM，Uhrich TD.The efficacy of dexmedetomidine versus morphine for postoperative analgesia after major in patient surgery[J].Anesth Analg，2004，98（1）：153-158.
|
| [11] |
Tomar GS，Singh F，Ganguly S，et al.Is dexmedetomidine better than propofol and fentanyl combination in minor day care procedures？A prospective randomised double-blind study[J].Indian J Anaesth，2015，59（6）：359-364.
|
| [12] |
Schnabel A，FrieBem CH，Reichl SU，et al.Is intraoperative dexmedetomidine a new option for postoperative pain treatment？A meta-analysis of randomized controlled trials[J].Pain，2013，154（7）：1140-1149.
|
| [13] |
Ebert TJ，Hall JE，Barney JA，et al.The effects of increasing plasma concentrations of dexmedetomidine in humans[J].Anesthesiology，2000，93（2）：382-394.
|
| [14] |
Ruan X，Mancuso KF，Kaye AD.Revisiting Oxycodone Analgesia：A Review and Hypothesis[J].Anesthesiol Clin，2017，35（2）：e163-e174.
|
| [15] |
Lemberg KK，Heiskanen TE，Kontinen VK，et al.Pharmacology of oxycodone：does it explain why oxycodone has become a best selling strong opioid?[J].Scand J Pain，2009，Suppl 1：S18-S23
|
| [16] |
Choi BM，Lee YH，An SM，et al.Population pharmacokinetics and analgesic potency of oxycodone[J].Br J Clin Pharmacol，2017，83（2）：314-325.
|
|
|
|
